A new trading day began on Monday, with Trevi Therapeutics Inc (NASDAQ: TRVI) stock price up 4.02% from the previous day of trading, before settling in for the closing price of $6.09. TRVI’s price has ranged from $2.36 to $7.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 7.67%. With a float of $69.87 million, this company’s outstanding shares have now reached $99.89 million.
In an organization with 26 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 43.98%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 7.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.45% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Here are Trevi Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.62 million. That was inferior than the volume of 1.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.68%. Additionally, its Average True Range was 0.46.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 69.47%, which indicates a significant increase from 45.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.23% in the past 14 days, which was lower than the 79.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.30, while its 200-day Moving Average is $4.49. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $6.44. Second resistance stands at $6.55. The third major resistance level sits at $6.73. If the price goes on to break the first support level at $6.15, it is likely to go to the next support level at $5.97. Assuming the price breaks the second support level, the third support level stands at $5.86.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
With a market capitalization of 754.78 million, the company has a total of 117,293K Shares Outstanding. Currently, annual sales are 0 K while annual income is -47,910 K. The company’s previous quarter sales were 0 K while its latest quarter income was -10,340 K.
